pd 98059 has been researched along with Cardiovascular Stroke in 26 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cardioprotective effects were found over a broad dosage range." | 1.39 | Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil. ( Böhme, S; Ebner, A; Ebner, B; Reetz, A; Schauer, A; Strasser, RH; Weinbrenner, C, 2013) |
| "Post-myocardial infarction ventricular remodeling is associated with the expression of a variety of factors including S100B that can potentially modulate myocyte apoptosis." | 1.36 | S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. ( Desjardins, JF; Huttunen, HJ; Izhar, S; Leong-Poi, H; Parker, TG; Tsoporis, JN, 2010) |
| "The protective effect of the SAFE pathway is shown in IPostC, with the activation of TNFalpha, its receptor type 2, and STAT-3." | 1.35 | Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. ( Lacerda, L; Lecour, S; Opie, LH; Somers, S, 2009) |
| "Olprinone was also examined with an intracoronary cotreatment with a PKA inhibitor (H89), a PKC inhibitor (GF109203X), an extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059), or a p38 MAPK inhibitor (SB203580) throughout the preischemic period." | 1.31 | Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. ( Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (69.23) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y | 1 |
| Xie, KL | 1 |
| Wu, HL | 1 |
| Wu, K | 1 |
| Ebner, B | 1 |
| Ebner, A | 1 |
| Reetz, A | 1 |
| Böhme, S | 1 |
| Schauer, A | 1 |
| Strasser, RH | 1 |
| Weinbrenner, C | 1 |
| Jiang, M | 1 |
| Wang, L | 1 |
| Jiang, HH | 1 |
| Thomas, CJ | 1 |
| Lim, NR | 1 |
| Kedikaetswe, A | 1 |
| Yeap, YY | 1 |
| Woodman, OL | 1 |
| Ng, DC | 1 |
| May, CN | 1 |
| Jin, YC | 1 |
| Kim, KJ | 1 |
| Kim, YM | 1 |
| Ha, YM | 1 |
| Kim, HJ | 1 |
| Yun, UJ | 1 |
| Bae, KH | 1 |
| Kim, YS | 1 |
| Kang, SS | 1 |
| Seo, HG | 1 |
| Lee, JH | 1 |
| Chang, KC | 1 |
| Das, A | 1 |
| Salloum, FN | 1 |
| Xi, L | 1 |
| Rao, YJ | 1 |
| Kukreja, RC | 1 |
| Lee, SW | 2 |
| Kang, HJ | 1 |
| Lee, JY | 1 |
| Youn, SW | 1 |
| Won, JY | 1 |
| Kim, JH | 1 |
| Lee, HC | 1 |
| Lee, EJ | 1 |
| Oh, SI | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Lacerda, L | 1 |
| Somers, S | 1 |
| Opie, LH | 1 |
| Lecour, S | 1 |
| Bopassa, JC | 1 |
| Eghbali, M | 1 |
| Toro, L | 1 |
| Stefani, E | 1 |
| Tsoporis, JN | 1 |
| Izhar, S | 1 |
| Leong-Poi, H | 1 |
| Desjardins, JF | 1 |
| Huttunen, HJ | 1 |
| Parker, TG | 1 |
| She, T | 1 |
| Wang, X | 1 |
| Gan, Y | 1 |
| Kuang, D | 1 |
| Yue, J | 1 |
| Ni, J | 1 |
| Zhao, X | 1 |
| Wang, G | 1 |
| Li, ZL | 1 |
| Hu, J | 1 |
| Li, YL | 1 |
| Xue, F | 1 |
| Zhang, L | 1 |
| Xie, JQ | 1 |
| Liu, ZH | 1 |
| Li, H | 1 |
| Yi, DH | 1 |
| Liu, JC | 1 |
| Wang, SW | 1 |
| Schulman, D | 1 |
| Latchman, DS | 3 |
| Yellon, DM | 4 |
| Hilfiker-Kleiner, D | 1 |
| Kaminski, K | 1 |
| Kaminska, A | 1 |
| Fuchs, M | 1 |
| Klein, G | 1 |
| Podewski, E | 1 |
| Grote, K | 1 |
| Kiian, I | 1 |
| Wollert, KC | 1 |
| Hilfiker, A | 1 |
| Drexler, H | 1 |
| Chintalgattu, V | 1 |
| Katwa, LC | 1 |
| Hausenloy, DJ | 1 |
| Mocanu, MM | 2 |
| Shu, E | 1 |
| Matsuno, H | 1 |
| Akamastu, S | 1 |
| Kanno, Y | 1 |
| Suga, H | 1 |
| Nakajima, K | 1 |
| Ishisaki, A | 1 |
| Takai, S | 1 |
| Kato, K | 1 |
| Kitajima, Y | 1 |
| Kozawa, O | 1 |
| Bell, RM | 1 |
| Clark, JE | 1 |
| Hearse, DJ | 1 |
| Shattock, MJ | 1 |
| Ruusalepp, A | 1 |
| Czibik, G | 1 |
| Flatebø, T | 1 |
| Vaage, J | 1 |
| Valen, G | 1 |
| Hu, Y | 1 |
| Chen, X | 1 |
| Pan, TT | 1 |
| Neo, KL | 1 |
| Khin, ES | 1 |
| Moore, PK | 1 |
| Bian, JS | 1 |
| Pagel, PS | 1 |
| Krolikowski, JG | 1 |
| Shim, YH | 1 |
| Venkatapuram, S | 1 |
| Kersten, JR | 1 |
| Weihrauch, D | 1 |
| Warltier, DC | 1 |
| Pratt, PF | 1 |
| Brar, BK | 2 |
| Jonassen, AK | 1 |
| Stephanou, A | 1 |
| Santilli, G | 1 |
| Railson, J | 1 |
| Knight, RA | 1 |
| Strohm, C | 1 |
| Barancik, T | 1 |
| Brühl, ML | 1 |
| Kilian, SA | 1 |
| Schaper, W | 1 |
| Chen, MM | 1 |
| Lam, A | 1 |
| Abraham, JA | 1 |
| Schreiner, GF | 1 |
| Joly, AH | 1 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Papst, PJ | 1 |
| Asanuma, H | 1 |
| Node, K | 1 |
| Takashima, S | 1 |
| Asakura, M | 1 |
| Ogita, H | 1 |
| Liao, Y | 1 |
| Sakata, Y | 1 |
| Ogai, A | 1 |
| Fukushima, T | 1 |
| Yamada, J | 1 |
| Shinozaki, Y | 1 |
| Kuzuya, T | 1 |
| Mori, H | 1 |
| Terada, N | 1 |
| Hori, M | 1 |
| Baxter, GF | 1 |
26 other studies available for pd 98059 and Cardiovascular Stroke
| Article | Year |
|---|---|
Functional suppression of Epiregulin impairs angiogenesis and aggravates left ventricular remodeling by disrupting the extracellular-signal-regulated kinase1/2 signaling pathway in rats after acute myocardial infarction.
Topics: Animals; Diastole; Electrocardiography; Epiregulin; Flavonoids; Heart Function Tests; Hemodynamics; | 2019 |
Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.
Topics: Animals; Cardiotonic Agents; Cyclic GMP; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imi | 2013 |
[Role of spinal MAPK-ERK signal pathway in myocardial ischemia-reperfusion injury].
Topics: Animals; Apoptosis; Flavonoids; Male; MAP Kinase Signaling System; Myocardial Infarction; Myocardial | 2013 |
Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3',4'-dihydroxyflavonol.
Topics: Animals; Cardiotonic Agents; Chromones; Drug Therapy, Combination; Female; Flavonoids; Flavonols; MA | 2015 |
Anti-apoptotic effect of magnolol in myocardial ischemia and reperfusion injury requires extracellular signal-regulated kinase1/2 pathways in rat in vivo.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspase 3; Disease Models, Animal; Flavonoids; Heart; Lignan | 2008 |
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.
Topics: Animals; bcl-2-Associated X Protein; Cardiovascular Agents; Cyclic GMP-Dependent Protein Kinases; Cy | 2009 |
Oscillating pressure treatment upregulates connexin43 expression in skeletal myoblasts and enhances therapeutic efficacy for myocardial infarction.
Topics: Animals; Cell Hypoxia; Cells, Cultured; Connexin 43; Extracellular Signal-Regulated MAP Kinases; Fla | 2009 |
Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway.
Topics: Androstadienes; Animals; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Flavono | 2009 |
A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury.
Topics: Adenosine Triphosphate; Animals; Blotting, Western; Enzyme Inhibitors; Extracellular Signal-Regulate | 2010 |
S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction.
Topics: Animals; Apoptosis; Butadienes; Caspase 3; Cell Line; Cytochromes c; Cytosol; Disease Models, Animal | 2010 |
Hyperglycemia suppresses cardiac stem cell homing to peri-infarcted myocardium via regulation of ERK1/2 and p38 MAPK activities.
Topics: Animals; Cell Movement; Cells, Cultured; Diabetes Mellitus, Experimental; Extracellular Signal-Regul | 2012 |
The effect of hyperoside on the functional recovery of the ischemic/reperfused isolated rat heart: potential involvement of the extracellular signal-regulated kinase 1/2 signaling pathway.
Topics: Animals; Cardiac Surgical Procedures; Caspase 3; Creatine Kinase; Flavonoids; L-Lactate Dehydrogenas | 2013 |
Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway.
Topics: Animals; Blood Gas Analysis; Blood Pressure; Corticotropin-Releasing Hormone; Enzyme Inhibitors; Fla | 2002 |
Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation.
Topics: Alkaloids; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoat | 2004 |
Role of protein kinase Cdelta in endothelin-induced type I collagen expression in cardiac myofibroblasts isolated from the site of myocardial infarction.
Topics: Acetophenones; Animals; Apoptosis; Benzopyrans; Binding Sites; Blotting, Western; Collagen Type I; E | 2004 |
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning.
Topics: Animals; Blotting, Western; Enzyme Inhibitors; Flavonoids; Ischemic Preconditioning, Myocardial; Mal | 2004 |
alphaB-crystallin is phosphorylated during myocardial infarction: involvement of platelet-derived growth factor-BB.
Topics: alpha-Crystallin B Chain; Animals; Becaplermin; Blotting, Western; Disease Models, Animal; Enzyme In | 2005 |
Reperfusion kinase phosphorylation is essential but not sufficient in the mediation of pharmacological preconditioning: Characterisation in the bi-phasic profile of early and late protection.
Topics: Androstadienes; Angiotensin II; Animals; Blotting, Western; Extracellular Signal-Regulated MAP Kinas | 2007 |
Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases.
Topics: Animals; Coronary Circulation; Enzyme Inhibitors; Flavonoids; Hyperoxia; Male; Mice; Mice, Inbred C5 | 2007 |
Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways.
Topics: Animals; Benzophenanthridines; Cardiotonic Agents; Cell Survival; Chromones; Disease Models, Animal; | 2008 |
Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo.
Topics: Androstadienes; Animals; Argon; Atractyloside; Cardiotonic Agents; Disease Models, Animal; Enzyme Ac | 2007 |
Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway.
Topics: Animals; Cell Death; Cell Hypoxia; Cells, Cultured; Corticotropin-Releasing Hormone; Flavonoids; Hea | 2000 |
Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium.
Topics: Animals; Blotting, Western; Butadienes; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Flav | 2000 |
CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.
Topics: Adult; Aged; Animals; Animals, Newborn; Biomarkers; Blotting, Northern; Cells, Cultured; Colforsin; | 2000 |
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-D | 2001 |
Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Hypoxia; Cells, Cultured; Enzyme Inhibitors; Flavonoids; | 2001 |